Survodutide posted 13.4% placebo-controlled weight loss at 76 weeks in the SYNCHRONIZE-1 Phase 3 trial, solid enough to clear both primary endpoints, but not enough to impress Wall Street.\n\nThe Boehringer Ingelheim and Zealand Pharma drug, a glucagon/GLP-1 dual agonist, produced an average 39.2 lbs of weight loss from baseline in the trial. Analysts quickly ran the comparisons. William Blair put it bluntly: survodutide is “more akin to Wegovy than Zepbound,” pointing to Novo Nordisk’s 14.4% loss versus survodutide’s 13.4%. Eli Lilly’s tirzepatide (Zepbound) hit 20.1% placebo-adjusted weight loss at 72 weeks in SURMOUNT-1 — a 6.7-point gap that’s hard to explain away.\n\nBMO Capital Markets called the data “underwhelms.” The responder analysis backs that read: in SYNCHRONIZE-1, 85% of survodutide patients lost at least 5% of body weight versus 39% on placebo. Zepbound’s figure was 96% versus 28%; Wegovy’s was 92% versus 33%.\n\nZealand flagged one potential bright spot: weight reduction was driven mainly by fat loss, with lean mass contributing “only a small proportion of total weight.” BMO wasn’t sold. The firm noted it “remains unclear what proportion of weight loss was specifically from fat loss.”\n\nSurvodutide’s best shot at differentiation may come from SYNCHRONIZE-MASLD, a Phase 3 study evaluating the drug in patients with obesity or overweight who also have metabolic dysfunction-associated steatohepatitis. Results are due later this year.\n\n— Sarah Chen